stockrow
Friday 6 November 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
- EPS
- −77.1%
- Free cash flow
- −201.4%
Quarter to June 2026, against a year earlier
71.42
4.20
+6.25%
Follow MNPR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 28 | 28 | 85 | +73.2% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | (1) | (17) | (3) | (4) | (6) | (9) | (11) | (8) | (16) | (14) | (18) | +31.3% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (1) | (17) | (3) | (4) | (6) | (9) | (11) | (8) | (16) | (14) | (18) | +31.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.11) | (9.43) | (1.74) | (2.25) | (2.90) | (3.65) | (4.15) | (3.05) | (4.11) | (1.85) | (2.17) | +36.8% | ||||||
| Cash flow | (0.11) | (1.50) | (1.44) | (1.62) | (2.13) | (2.93) | (2.84) | (2.84) | (1.69) | (1.65) | (1.43) | +34.7% | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.11) | (1.50) | (1.44) | (1.62) | (2.13) | (2.93) | (2.84) | (2.84) | (1.69) | (1.65) | (1.43) | +34.7% | ||||||
| Book value | 0.27 | 5.48 | 3.72 | 6.77 | 7.16 | 7.59 | 3.97 | 2.02 | 14.52 | 18.60 | 15.32 | +60.2% | ||||||
| Shares, m | 11 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 7 | 8 | (3.9%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (3) | (3) | (3) | (5) | (7) | (7) | (8) | (6) | (12) | (12) | +29.5% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | (1) | (3) | (3) | (3) | (5) | (7) | (7) | (8) | (6) | (12) | (12) | +29.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 2 | 9 | 7 | 13 | 16 | 19 | 10 | 6 | 55 | 138 | 131 | +59.8% | |||||
| Net debt | (2) | (9) | (7) | (13) | (17) | (20) | (13) | (7) | (60) | (140) | (134) | +59.7% | ||||||
| Shareholders’ equity | 3 | 10 | 7 | 13 | 16 | 19 | 10 | 6 | 55 | 138 | 131 | +54.0% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (18.49) | (258.13) | (37.43) | (40.88) | (41.72) | (48.69) | (62.32) | (81.68) | (46.09) | (13.65) | (18.90) | +4.8 pt | |||||
| ROIC | 0.00 | (1,627.75) | (8,132.57) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (19.05) | (265.94) | (39.04) | (43.23) | (44.52) | (52.57) | (72.44) | (107.19) | (51.42) | (14.22) | (19.50) | +4.8 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | 5 | 5 | 10 | 10 | 12 | 10 | 16 | 22 | — | +23.6% | |||||
| Revenue/emp, $m | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Monopar Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MDXG MiMedx Group, Inc | $478.6M | — (loss-making) | — (loss-making) | −45.23% (below 0%: shrinking) | n/m | −87.21% (below 0%: shrinking) | 79.80% | (18.79%) | Compare |
| CTMX CytomX Therapeutics, Inc. | $466.3M | — (loss-making) | — (loss-making) | −71.69% (below 0%: shrinking) | n/m | +204.14% (above 0%: growing) | 100.00% | (1,392.30%) | Compare |
| ETRA Electra Therapeutics Inc. | $461.3M | — | — | — | — | — | — | — | Compare |
| MNPR Monopar Therapeutics Inc. | $451.2M | — (loss-making) | — | — | n/m | −201.41% (below 0%: shrinking) | — | 0.00% | |
| STTK Shattuck Labs, Inc. | $450.6M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EPRX Eupraxia Pharmaceuticals Inc. | $429.1M | — (loss-making) | — | — | n/m | −56.41% (below 0%: shrinking) | — | 0.00% | Compare |
| ARVN Arvinas, Inc. | $428.9M | — (loss-making) | — (loss-making) | −98.81% (below 0%: shrinking) | n/m | +82.77% (above 0%: growing) | 80.00% | (11,820.00%) | Compare |
| GYRE Gyre Therapeutics, Inc. | $425.2M | — (loss-making) | — (loss-making) | +7.75% (above 0%: growing) | n/m | −129.91% (below 0%: shrinking) | 94.09% | 0.00% | Compare |
| PRTCY PureTech Health PLC Sponsored ADR | $424.0M | — (loss-making) | — (loss-making) | −44.60% (below 0%: shrinking) | +66.43% (above 0%: growing) | +19.27% (above 0%: growing) | 2.83% | 0.00% | Compare |
| Median of peers | $439.9M | — | — | −44.91% | — | +1.01% | 87.05% | 0.00% |
Pay and ownership Proxy statement filed 30 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 10.64m | 17.38m | 3,838.92 |
| 2024 | 1.14m | 2.36m | 185.65 |
| 2023 | 1.78m | (166.18k) | 14.35 |
Ownership
Directors and executive officers, together
9.70%
Janus Henderson Group plc
17.50%
RA Capital Management, L.P.
10.00%
Diane Hendricks
9.90%
Adage Capital Management, L.P.
8.90%
AstraZeneca PLC
7.80%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement